Six-Country Study of Modified Release Prednisone for Rheumatoid Arthritis Now Recruiting

Patients with active rheumatoid arthritis – including both morning stiffness and swollen and tender joints – ages 18-80 are wanted for a 12-week study to determine the relative ability of a new modified-release prednisone formulation to reduce morning stiffness and swollen joints.

The large placebo-controlled trial, which is recruiting internationally at 51 study locations in the U.S., Canada (Ontario), Germany, Hungary, Poland, and the United Kingdom, will involve once-a-day dosing with the time-release prednisone tablet (Lodotra®).

To learn more about specific inclusion and exclusion criteria, review the study locations, and direct questions to the Nitec Pharma contact center (, see the listing for the trial – “Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra) Therapy in Patients with Active Rheumatoid Arthritis” – ( and mention Trial ID NCT00650078.

1 Star2 Stars3 Stars4 Stars5 Stars (5 votes, average: 3.80 out of 5)

Leave a Reply